Your browser doesn't support javascript.
loading
A preliminary study of bowel rest strategy in the management of Clostridioides difficile infection.
Sugimoto, Hiroshi; Yoshihara, Ayaka; Yamamoto, Takao; Sugimoto, Keisuke.
Afiliación
  • Sugimoto H; Department of Respiratory Medicine, Kobe Red Cross Hospital, 1-3-1 Wakinohama Kaigan-dori, Chuo-ku, Kobe, 651-0073, Japan. dr.sugimoto@gmail.com.
  • Yoshihara A; Department of Respiratory Medicine, Kobe Red Cross Hospital, 1-3-1 Wakinohama Kaigan-dori, Chuo-ku, Kobe, 651-0073, Japan.
  • Yamamoto T; Department of Gastroenterology, Kobe Red Cross Hospital, Kobe, Japan.
  • Sugimoto K; Department of Respiratory Medicine, Kobe Red Cross Hospital, 1-3-1 Wakinohama Kaigan-dori, Chuo-ku, Kobe, 651-0073, Japan.
Sci Rep ; 10(1): 22061, 2020 12 16.
Article en En | MEDLINE | ID: mdl-33328505
ABSTRACT
Clostridioides difficile infection (CDI) is an important nosocomial infection and is the leading cause of infectious diarrhea in hospitalized patients. We aimed to assess the effect of bowel rest on the management of CDI. A single-center retrospective cohort study was conducted. The primary outcome was the composite of the all-cause mortality and CDI recurrence within 30 days. The main secondary outcome was switching from metronidazole to vancomycin. Of the 91 patients with CDI enrolled as the full cohort, 63 patients (69%) and 28 patients (31%) constituted the control group and the bowel rest group, respectively. After one-to-one propensity score matching, a total of 46 patients were included as the matched cohort. In the full cohort, the composite outcome occurred in 19.0% and 14.3% of the patients in the control and the bowel rest group, respectively (p = 0.768). In the matched cohort, it was 17.4% in each group. Although there was no statistically significant difference, the trend of switching was lower in the bowel rest group. The bowel rest may not affect the all-cause mortality and CDI recurrence within 30 days. However, in those prescribed bowel rest, switching from metronidazole to vancomycin may reduce.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 / 3_ND / 4_TD Problema de salud: 2_enfermedades_transmissibles / 3_diarrhea / 3_neglected_diseases / 4_diarrhoeal_infections Asunto principal: Vancomicina / Clostridioides difficile / Infecciones por Clostridium / Diarrea / Metronidazol Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Sci Rep Año: 2020 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 / 3_ND / 4_TD Problema de salud: 2_enfermedades_transmissibles / 3_diarrhea / 3_neglected_diseases / 4_diarrhoeal_infections Asunto principal: Vancomicina / Clostridioides difficile / Infecciones por Clostridium / Diarrea / Metronidazol Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male Idioma: En Revista: Sci Rep Año: 2020 Tipo del documento: Article País de afiliación: Japón
...